CSF3 and neutropenia: The phase I study of Pronk et al (1998) that has evaluated the feasibility of the docetaxel–ifosfamide combination without G-CSF in pretreated patients with a variety of advanced solid tumours determined the DLT of the combination being mainly neutropenia at the following doses; docetaxel 85 mg m−2 on day 1 followed by ifosfamide 5 g m−2 administered as 24-h infusion, and the recommended phase II doses were docetaxel 75 mg m−2 +ifosfamide 5 g m−2 (Pronk et al, 1998).